CultivO2

Company Overview

Snapshot

Founded in May 2024 by Dr. Michal, Michal Breker-Dekel, and Ofra Benny, CultivO2 operates with 1–10 employees. The company has secured one funding round from one investor. In May 2024, CultivO2 received Seed funding from Fresh Start.

Business overview

CultivO2 is developing an innovative bio convergence platform for the autonomic culture of animal tissue. Its core technology utilizes photosynthetic microalgae to create a symbiotic recycling system that continuously excretes oxygen, growth factors, and glucose while consuming toxic by-products. This platform aims to reduce the need for bioreactors in tissue culture, enabling cost reduction and scalability for cultured meat production. The company serves the food industry and operates within the Agriculture & Food Technologies sector, specifically focusing on Food Tech and Novel Food & Ingredients.

Company Intelligence Q&A

What is CultivO2's primary focus?

CultivO2 focuses on developing a bio convergence platform for the autonomic culture of animal tissue, aiming to enable cost reduction and scalability for cultured meat production.

When was CultivO2 founded?

CultivO2 was founded in May 2024.

Who are the founders of CultivO2?

The founders of CultivO2 are Dr. Michal, Michal Breker-Dekel, and Ofra Benny.

What kind of funding has CultivO2 received?

CultivO2 received Seed funding from Fresh Start in May 2024.

What is the core technology behind CultivO2's platform?

CultivO2's core technology involves utilizing photosynthetic microalgae to create a live oxygen-producing biomaterial that supports animal tissue cells by providing oxygen, growth factors, and glucose, while consuming toxic by-products.